Search - tctmd.com

Displaying 41 - 60 of 379

Sort: Relevancy | Date

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Michael O'Riordan

February 29, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Daily News

Even Low Levels of ApoB and LDL Linked With CAD, Mortality: UK Biobank

Michael O'Riordan

January 23, 2024

News Daily News

Top General Cardiology and CVD Prevention News of 2023

Yael L. Maxwell

January 03, 2024

News Opinion Editor's Corner

The Biggest News of 2023: TCTMD’s Top 10

Shelley Wood

January 01, 2024

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Daily News

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

Caitlin E. Cox

December 06, 2023

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

Advertisement

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High-Risk ‘Clues’ Add Heft to Calcium Scores in Primary Prevention

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

February 2024 Dispatch for the CV Team

Even Low Levels of ApoB and LDL Linked With CAD, Mortality: UK Biobank

Top General Cardiology and CVD Prevention News of 2023

The Biggest News of 2023: TCTMD’s Top 10

Top Coronary Artery Disease News of 2023

PAD, AAA: High Lp(a) Portends Problems Beyond CVD

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Mortality Risk Varies Among Patients With Very High LDL Levels

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

What’s Going to Be Hot at AHA 2023

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content